13F-HR: NVIDIA Corp's 13F Filing Reveals Key Equity Holdings

NVIDIA Corp's latest 13F filing discloses significant investments in several technology companies, including ARM Holdings and Recursion Pharmaceuticals.

Summary

• NVIDIA Corp's 13F filing for the quarter ended December 31, 2023, reveals a total portfolio value of $230,419,085 across five holdings.
• The largest holding is in ARM Holdings PLC, with a value of $147,343,114 representing 1,960,784 shares.
• Recursion Pharmaceuticals is the second largest holding with a value of $75,984,739 representing 7,706,363 shares.
• Other holdings include Nano X Imaging Ltd, SoundHound AI Inc, and TuSimple Holdings Inc.
• The filing indicates that NVIDIA has sole voting authority over the shares in ARM Holdings, Recursion Pharmaceuticals and SoundHound AI Inc.
• NVIDIA has 'defined' voting authority over the shares in Nano X Imaging Ltd and TuSimple Holdings Inc.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of holdings, indicating a stable and strategic investment approach. The investments in key technology sectors are positive, but the lack of forward-looking statements keeps the sentiment from being higher.

Positives

• NVIDIA has a significant investment in ARM Holdings, indicating a strong position in the semiconductor industry.
• The investment in Recursion Pharmaceuticals suggests a strategic interest in the biotechnology and AI-driven drug discovery space.
• The diverse portfolio indicates a broad investment strategy across different technology sectors.

Risks

• The performance of NVIDIA's portfolio is subject to market fluctuations and the specific risks associated with each of the companies they have invested in.
• Changes in the technology sector could impact the value of these holdings.

Industry Context

This filing reflects NVIDIA's strategic investments in key technology sectors, including semiconductors, AI, and biotechnology, aligning with broader industry trends of convergence and innovation.

Comparison to Industry Standards

• NVIDIA's investment in ARM Holdings is consistent with other major tech companies seeking exposure to the semiconductor design space, similar to investments by companies like Apple and Qualcomm.
• The investment in Recursion Pharmaceuticals is comparable to other tech companies' forays into AI-driven drug discovery, such as Google's investments in DeepMind's healthcare initiatives.
• The portfolio diversification across AI, biotech, and autonomous driving reflects a broader trend of tech companies investing in multiple high-growth sectors, similar to the strategies of companies like SoftBank and Alphabet.

Stakeholder Impact

• Shareholders can gain insight into NVIDIA's investment strategy and portfolio composition.
• The investments may impact the share prices of the companies NVIDIA has invested in.
• The filing provides transparency into NVIDIA's financial activities.

Key Dates

Keywords

13F Filing, NVIDIA, ARM Holdings, Recursion Pharmaceuticals, Institutional Investment, Technology Investments, Equity Holdings